Status: Available
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will: * Use BRM421 two times a day for at least 12 weeks * Visit the clinic monthly for checkups and tests
Trial details
Age: 18+Biological sex: AllType: Expanded AccessSponsor: BRIM Biotechnology Inc.Updated: Feb 20, 2026Locations: 1
Eligibility criteria
Adult patients with mild to moderate LSCD who unsatisfied with the standard of c... [+2]
The patients eligible for the BRIM clinical trial(s). [+3]